Ray Dalio
PTGX icon

Ray Dalio’s Protagonist Therapeutics PTGX Stock Holding History

Ray Dalio’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$556K Buy
+5,276
New +$467K ﹤0.01% 868

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Ray Dalio's PTGX Position: Q1 2026 in Review

Ray Dalio opened a new position in Protagonist Therapeutics (PTGX) in Q1 2026: 5,276 shares worth $556K. The stake represents ﹤0.01% of the portfolio and ranks #868 among its holdings.

319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Ray Dalio held 5,276 shares of Protagonist Therapeutics worth $556K as of Q1 2026.
  • Protagonist Therapeutics was a new Ray Dalio position in Q1 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Ray Dalio's portfolio in Q1 2026, its #868 holding.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.